Reuters logo
3 个月内
BRIEF-Auris Medical reports key results from Keyzilen Ampact2 open-label extension study
2017年4月24日 / 下午12点35分 / 3 个月内

BRIEF-Auris Medical reports key results from Keyzilen Ampact2 open-label extension study

1 分钟阅读

April 24 (Reuters) - Auris Medical Holding Ag

* Auris medical reports key results from Keyzilen Ampact2 open-label extension study

* Trial outcomes show positive safety profile of Keyzilen for chronic intermittent use

* Exploratory efficacy results support therapeutic concept of early tinnitus treatment

* Says trial outcomes show positive safety profile of Keyzilen for chronic intermittent use

* Says auris medical expects to announce results from ampact1, open-label extension study related to TACTT2, later this quarter

* TACTT3 extended to recruit additional 60 patients in each of stratum A and B, enrollment ongoing; top-line results expected in early 2018

* As recruitment for Ampact2 has completed, open-label extension is not offered to patients currently enrolling in extended TACTT3 trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below